Loading…
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-122M | $-3M | $-116M | 2.8% | - | -97.9% |
| 2024 | $0M | $-155M | $-157M | $-149M | 85.9% | - | 33.1% |
| 2023 | $0M | $-143M | $-118M | $74M | 471.6% | - | -348.5% |
| 2022 | $0M | $-158M | $47M | $-87M | 55.3% | - | - |
| 2021 | - | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Cost Of Revenue | 0 | - | - | - | - |
| Gross Profit | 0 | - | - | - | - |
| Operating Expense | - | 163.39 | 164.53 | 166.95 | 122.80 |
| Research And Development | - | 112.72 | 114.87 | 119.52 | 81.30 |
| Selling General And Administration | - | 50.67 | 49.66 | 47.43 | 41.50 |
| Total Expenses | - | 163.39 | 164.53 | 166.95 | 122.80 |
| Operating Income | - | -163.39 | -164.53 | -166.95 | -122.80 |
| Total Operating Income As Reported | - | -163.39 | -164.53 | -166.95 | -122.80 |
| EBITDA | - | -158.38 | -143.16 | -154.70 | -121.83 |
| Normalized EBITDA | - | -158.38 | -147.27 | -154.72 | -236.78 |
| EBIT | - | -159.33 | -144.08 | -155.65 | -122.80 |
| Interest Income | - | 4.06 | 16.34 | 11.28 | 5.06 |
| Interest Expense | 19.67 | 22.70 | 30.84 | 24.68 | - |
| Net Interest Income | - | -18.64 | -14.50 | -13.39 | 5.06 |
| Other Non Operating Income Expenses | 1.74 | - | - | - | - |
| Other Income Expense | 1.74 | - | 4.11 | 0.02 | 114.94 |
| Interest Income Non Operating | - | 4.06 | 16.34 | 11.28 | 5.06 |
| Interest Expense Non Operating | 19.67 | 22.70 | 30.84 | 24.68 | - |
| Net Non Operating Interest Income Expense | - | -18.64 | -14.50 | -13.39 | 5.06 |
| Pretax Income | - | -182.03 | -174.92 | -180.32 | -2.80 |
| Tax Provision | - | 0 | 0 | 2.31 | 2.01 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 24.14 |
| Net Income Continuous Operations | - | -182.03 | -174.92 | -182.63 | -4.81 |
| Net Income From Continuing And Discontinued Operation | - | 47.42 | -117.81 | -156.82 | -3.35 |
| Net Income From Continuing Operation Net Minority Interest | - | -182.03 | -174.92 | -182.63 | -4.81 |
| Net Income | - | 47.42 | -117.81 | -156.82 | -3.35 |
| Net Income Common Stockholders | - | 47.42 | -117.81 | -156.82 | -3.35 |
| Net Income Including Noncontrolling Interests | - | 47.42 | -117.81 | -156.82 | -3.35 |
| Normalized Income | - | -182.03 | -179.03 | -182.64 | -95.61 |
| Diluted NI Availto Com Stockholders | - | 47.42 | -117.81 | -156.82 | -3.35 |
| Basic Average Shares | - | 62.74 | 62.74 | 58.17 | 63.51 |
| Diluted Average Shares | - | 62.74 | 62.74 | 58.17 | 63.51 |
| Reconciled Depreciation | - | 0.95 | 0.92 | 0.95 | 0.96 |
| Reconciled Cost Of Revenue | 0 | - | - | - | - |
| Total Unusual Items | - | 0 | 4.11 | 0.02 | 114.94 |
| Total Unusual Items Excluding Goodwill | - | 0 | 4.11 | 0.02 | 114.94 |
| Net Income Discontinuous Operations | - | 229.45 | 57.11 | 25.81 | 1.46 |
| Special Income Charges | - | 0 | 4.11 | 0 | 251.66 |
| Gain On Sale Of Business | - | - | - | - | 237.59 |
| Other Special Charges | - | - | -4.11 | - | -14.07 |
| Gain On Sale Of Security | - | - | - | 0.02 | -136.72 |
| General And Administrative Expense | - | 50.67 | 49.66 | 47.43 | 41.50 |
| Other Gand A | - | 42.63 | 42.52 | 41.07 | 36.84 |
| Salaries And Wages | - | 8.04 | 7.14 | 6.36 | 4.66 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Omeros Corporationthis co. | OMER | $742M | -221.45 | -6.12 | 2.8% | -7.97 |
| Geron Corporation | GERN | $776M | -9.30 | 3.44 | -37.0% | -16.53 |
| BioAge Labs, Inc. | BIOA | $757M | -9.39 | 2.78 | -29.6% | -7.19 |
| EVMN | EVMN | $745M | -10.82 | 3.63 | -33.5% | -8.82 |
| HealthStream, Inc. | HSTM | $739M | 40.28 | 2.09 |
| - |
| - |
| - |
| 5.2% |
| 11.26 |
| Bright Minds Biosciences Inc. | DRUG | $731M | -59.77 | 8.91 | -14.9% | -46.77 |
| Solid Biosciences Inc. | SLDB | $713M | -4.09 | 3.96 | -96.8% | -3.80 |
| CBLL | CBLL | $711M | -13.32 | 4.58 | -34.4% | -13.81 |
| Enhabit, Inc. | EHAB | $707M | -153.68 | 1.32 | -0.9% | 20.09 |
| Peer Median | - | -10.10 | 3.53 | -31.6% | -8.01 | |